Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(33.3%)
Phase 1
1(33.3%)
Phase 2
1(33.3%)
3Total
Phase 3(1)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01374308Phase 3Unknown

NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients

Role: lead

NCT01747642Phase 2Unknown

Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma

Role: lead

NCT01392131Phase 1Unknown

Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC)

Role: lead

All 3 trials loaded